Namwiwat Medical Corporation (NAM) Fair Value & Analysis
Healthcare · TH · Market cap 2.4B THB
Fair value as of: Jul 11, 2026
From 15 valuation models · updated 30 days ago
Fair value updated Jul 11, 2026, revised from 3.92 THB to 2.90 THB (−26.0%) since Jun 24, 2026. Share price −2.3% over the past month.
Below-average quality, and screening another 14% overvalued on our models.
What matters now
- Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
- Our model range runs from 2.18 THB (bear) to 3.63 THB (bull), base 2.90 THB. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 48/100 (below-average quality) with high evidence: the data supports the verdict.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.
How to read this chart
33‑month range 3.36 THB – 6.68 THB · fair‑value band 2.18 THB – 3.63 THB · the 3.36 THB price screens above the 2.90 THB fair value. Dashed = 300-day average. As of Jul 11, 2026.
Analysis
Namwiwat Medical Corporation (NAM) currently trades at 3.36 THB, while our model-based Fair Value estimate is 2.90 THB, implying the stock looks roughly 13.7% overvalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Namwiwat Medical Corporation generated revenue of 1.7B THB at a net margin of 4.0%. Revenue declined 29.9% year over year. It earns a return on equity of 3.4%. Net debt stands at 190M THB. Fundamentals as of Jul 11, 2026
Our scenario range runs from 2.18 THB (bear case) to 3.63 THB (bull case); at 3.36 THB, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -14%, NAM screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: DCF Models (5.35 THB) versus Asset-Based (1.91 THB). Highest evidence: Residual Income (76).
Notify me when NAM reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Namwiwat Medical Corporation Public Company Limited manufactures and distributes medical equipment in Thailand. The company offers steam and low temperature sterilizers, instrument washer disinfectors, ultrasonic cleaning systems, and drying cabinets, as well as waste sterilizers.
Full company description
Namwiwat Medical Corporation Public Company Limited manufactures and distributes medical equipment in Thailand. The company offers steam and low temperature sterilizers, instrument washer disinfectors, ultrasonic cleaning systems, and drying cabinets, as well as waste sterilizers. It also provides NAMTrack, a central sterile supply department software management product, as well as Air Track. In addition, the company offers air and surface disinfection equipment and air purifiers. Further, it provides medical supplies, disinfection services, medical equipment maintenance services, infectious waste services, and other medical services. The company was founded in 1970 and is based in Samut Prakan, Thailand.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Namwiwat Medical Corporation reported revenue of 1.9B THB in FY2026 versus 992M THB in FY2022, a compound +17.2%/yr. Reported net income was 102M THB in FY2026, compounding −12.7%/yr from FY2022.
NAM screens 14% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Namwiwat Medical Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Namwiwat Medical Corporation (NAM) overvalued or undervalued?
What is the fair value of NAM?
What is the quality score of NAM?
What is the revenue of Namwiwat Medical Corporation (NAM)?
What is the net profit margin of NAM?
Does Namwiwat Medical Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Namwiwat Medical Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.